TargetBeta
SLC12A1
solute carrier family 12 member 1 · also NKCC2, CCC2, BSC1, BSC · Solute carrier family 12
2 programs in company-led studies act on SLC12A1, from 2 companies: 0 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Furosemiderule | Boehringer Ingelheim | phase 4 | 271 running | – | ChEMBL |
| Torsemiderule | Sarfez Pharmaceuticals | phase 4 | 131 running | – | ChEMBL |
Conditions their studies are in
- Heart Failure, 2 programs
- Body Weight Changes, 1 program
- Diabetes Mellitus, 1 program
- Diabetes Mellitus, Type 2, 1 program
- Edema, 1 program
- Hypertension, 1 program
- Liver Cirrhosis, 1 program
- Pulmonary Arterial Hypertension, 1 program
- Warts, 1 program
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.